InMode News

UBS Adjusts Price Target on InMode to $20 From $26, Maintains Neutral Rating

MT NewswiresMay 3 23:41

Needham: Reiterates that InMode (INMD.US) holds the rating.

Zhitong FinanceMay 3 18:20

InMode Analyst Ratings

BenzingaMay 3 18:16

Analysts Conflicted on These Healthcare Names: InMode (INMD) and Pfizer (PFE)

TipRanksMay 3 04:10

Barclays: Maintaining the InMode (INMD.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $34.00 to $33.00.

Zhitong FinanceApr 12 22:01

InMode Analyst Ratings

BenzingaApr 12 21:58

Barclays Maintains Overweight on InMode, Lowers Price Target to $33

BenzingaApr 12 21:59

Barclays Keeps Their Buy Rating on InMode (INMD)

TipRanksApr 12 15:35

Analysts Are Bullish on Top Healthcare Stocks: InMode (INMD), Resmed (RMD)

TipRanksApr 12 13:50

Needham Sticks to Their Hold Rating for InMode (INMD)

TipRanksApr 9 23:56

InMode Analyst Ratings

BenzingaApr 9 23:51

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), InMode (INMD) and Teladoc (TDOC)

TipRanksMar 6 21:10

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Evolent Health (EVH) and InMode (INMD)

TipRanksFeb 15 16:10

InMode Receives Buy Rating From Baird Analyst Amidst Promising Outlook and Undervalued Stock

TipRanksFeb 15 14:22

InMode Analyst Ratings

BenzingaFeb 15 03:54

UBS Adjusts InMode Price Target to $26 From $24, Maintains Neutral Rating

MT NewswiresFeb 15 01:31

Analysts Conflicted on These Healthcare Names: Anixa Biosciences (ANIX) and InMode (INMD)

TipRanksFeb 14 01:20

Analysts Offer Insights on Healthcare Companies: MaxCyte (GB:MXCT), Kura Oncology (KURA) and InMode (INMD)

TipRanksJan 23 17:09

InMode Analyst Ratings

BenzingaJan 18 22:07

Barclays Maintains Overweight on InMode, Lowers Price Target to $33

BenzingaJan 4 21:06